A Bay Area biotech company has laid off 55 employees, citing funding cuts linked to policies from the Trump administration — just three months after raising nearly $351 million in funding. In a ...

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

The acquisition marks a turning point for the company after months of financial uncertainty and data breach concerns.

A Bay Area biotech company that laid off dozens of people this week has blamed the job cuts on policies of the Trump administration. Eikon Therapeutics Inc. cut 55 jobs from its ...

The sale was for $256 million and is expected to be complete by the third quarter of this year, according to a Regeneron news ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Bankrupt DNA testing company 23andMe was purchased Monday by biotechnology company Regeneron for $256 million. Both companies ...

Leveraging Northway Biotech’s 20+ years of CDMO expertise, Kaida BioPharma is advancing KAD101, a targeted therapy for ...

Discover seven lung cancer companies advancing promising candidates through the clinic, from viral immunotherapies to ...

The Beachwood-based company announced on Tuesday, May 20, that it has appointed Dr. David Llewellyn as its new CEO and as a ...

A grantee of the Gates Foundation, Hong Kong-based Phase Scientific built a business on the back of Covid-19 tests. Up next: ...

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing ...